Skip to main content
. 2022 Mar 15;12:4398. doi: 10.1038/s41598-022-08449-w

Figure 4.

Figure 4

OS of post-progression (A) osimertinib treatment and (B) chemotherapy between EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy groups. bev bevacizumab, TKI tyrosin kinase inhibitor.